Last reviewed · How we verify
Inhaled Long-Acting Beta Agonist
Long-acting beta-2 agonists bind to beta-2 adrenergic receptors on airway smooth muscle, causing relaxation and bronchodilation with sustained effect over 12-24 hours.
Long-acting beta-2 agonists bind to beta-2 adrenergic receptors on airway smooth muscle, causing relaxation and bronchodilation with sustained effect over 12-24 hours. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy, Asthma maintenance therapy.
At a glance
| Generic name | Inhaled Long-Acting Beta Agonist |
|---|---|
| Sponsor | Sanofi |
| Drug class | Long-acting beta-2 agonist (LABA) |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
These agents activate beta-2 adrenergic receptors on bronchial smooth muscle, triggering increased intracellular cAMP and leading to smooth muscle relaxation and airway dilation. The long-acting formulation provides sustained bronchodilation, reducing airway obstruction and improving airflow. LABAs are typically used in combination with inhaled corticosteroids for maintenance therapy in chronic obstructive pulmonary disease and asthma.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
- Asthma maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Nervousness
Key clinical trials
- Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting
- Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma (PHASE2)
- A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma (PHASE2)
- Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation (NA)
- Fractional Exhaled Nitric Oxide and Exacerbations of COPD
- Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma (PHASE4)
- Pressurized Meter Dose Inhaler V/S Dry Powder Inhaler (NA)
- Cardiovascular Consequences of Inhaled Short-acting Beta-agonist Use (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inhaled Long-Acting Beta Agonist CI brief — competitive landscape report
- Inhaled Long-Acting Beta Agonist updates RSS · CI watch RSS
- Sanofi portfolio CI